NCT06057909

Brief Summary

The purpose of this research study is to investigate how the brain, memory, thinking, and motor behavior change both in individuals with movement and/or cognitive disorders, as well as healthy individuals. Researchers will look at measurements of memory, thinking, brain wave and muscle activity, daily functioning, and brain scans to learn more about brain disorders such as Alzheimer disease and Lewy body disease.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
13mo left

Started Apr 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress66%
Apr 2024Jun 2027

First Submitted

Initial submission to the registry

September 21, 2023

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 28, 2023

Completed
6 months until next milestone

Study Start

First participant enrolled

April 5, 2024

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2027

Last Updated

February 3, 2026

Status Verified

January 1, 2026

Enrollment Period

3.2 years

First QC Date

September 21, 2023

Last Update Submit

January 30, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • Diffusion-weighted MRI (dMRI)

    Measures diffusion of water molecules and cellular-level constraints

    Baseline

  • Electroencephalography (EEG)

    Measures brain-wave activity

    Baseline

Study Arms (3)

Lewy Body Disease Group

Subjects identified by their physician with a diagnosis of Lewy body disease will have a physical and neurological exam, MRI of brain, electroencephalography (EEG), and electromyography (EMG).

Diagnostic Test: Magnetic Resonance ImagingDiagnostic Test: ElectroencephalographyDiagnostic Test: Electromyography

Alzheimer Disease Group

Subjects identified by their physician with a diagnosis of Alzheimer will have a physical and neurological exam, MRI of brain, electroencephalography (EEG), and electromyography (EMG).

Diagnostic Test: Magnetic Resonance ImagingDiagnostic Test: ElectroencephalographyDiagnostic Test: Electromyography

Healthy Control Group

Subjects identified as a health individual will have a physical and neurological exam, MRI of brain, electroencephalography (EEG), and electromyography (EMG).

Diagnostic Test: Magnetic Resonance ImagingDiagnostic Test: ElectroencephalographyDiagnostic Test: Electromyography

Interventions

Test that looks at the structure of the brain.

Also known as: MRI
Alzheimer Disease GroupHealthy Control GroupLewy Body Disease Group
ElectroencephalographyDIAGNOSTIC_TEST

Non-invasive technique to measure brain waves

Also known as: EEG
Alzheimer Disease GroupHealthy Control GroupLewy Body Disease Group
ElectromyographyDIAGNOSTIC_TEST

Technique to evaluate muscle activity

Also known as: EMG
Alzheimer Disease GroupHealthy Control GroupLewy Body Disease Group

Eligibility Criteria

Age50 Years - 95 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

This study will include healthy individuals, and patients who have a clinical diagnosis made by a board-certified neurologist of Lewy body disease or Alzheimer disease.

You may qualify if:

  • Use English as their primary language.
  • Be willing to undergo health and cognitive assessments, as well as brain MRI and EEG study.
  • Will be encouraged to have an available study partner (also called a "co-participant") who is familiar with the participant's daily functioning.
  • This study will be limited to healthy individuals, and patients who have a clinical diagnosis made by a board-certified neurologist of Lewy body disease or Alzheimer disease.
  • All individuals must be capable of providing informed consent and complying with the trial procedures. Realizing the challenge of obtaining informed consent from cognitively impaired individuals, time is specifically scheduled to foster an informative, supportive interview with the participant and caregiver/legal guardian (typically a spouse or child according to Arizona law and IRB guidelines).

You may not qualify if:

  • All participants will receive copies of the signed ICFs (including signatures of those obtaining consent).
  • All participants have the right to withdraw from the study at any time.
  • Individuals will be excluded if they have significant sensory (visual and hearing) deficits or major medical or psychiatric illnesses which would limit participation.
  • Participants will also be excluded if they have history of other major neurologic disorders including stroke, epilepsy, meningitis/encephalitis, metabolic or toxic encephalopathy, penetrating or severe closed head injury, brain tumor/other structural lesion, other primary movement disorders (such as essential tremor, dystonia, chorea, multiple system atrophy, progressive supranuclear palsy, corticobasal syndrome).
  • In addition, as necessitated by the risks of Magnetic Resonance Imaging (MRI), patients who have any type of implanted electrical device (such as a cardiac pacemaker or a neurostimulator including deep brain stimulation), or a certain type of metallic clip in their body (i.e., an aneurysm clip in the brain), are not eligible for participation in the MRI portion of the study. Individuals who experience claustrophobic anxiety will also be excluded from participation.
  • Women who are or might be pregnant and nursing mothers are not eligible.
  • If the subject is a woman of childbearing potential, due to unknown risks to the fetus, they must have a pregnancy test. Individuals who have a history metalworking involving cutting processes such as grinding, filing, shaving, and threading, or history of eye injury involving metal, will also be excluded unless they have had prior documented radiological clearance for MRI.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mayo Clinic Arizona

Scottsdale, Arizona, 85268, United States

RECRUITING

Related Links

MeSH Terms

Conditions

Lewy Body DiseaseAlzheimer Disease

Interventions

Magnetic Resonance ImagingElectroencephalographyElectromyography

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesDementiaMovement DisordersSynucleinopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersTauopathies

Intervention Hierarchy (Ancestors)

TomographyDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisDiagnostic Techniques, NeurologicalElectrodiagnosisMyography

Study Officials

  • Shannon Chiu, MD

    Mayo Clinic

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

September 21, 2023

First Posted

September 28, 2023

Study Start

April 5, 2024

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

June 1, 2027

Last Updated

February 3, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Locations